Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Abildgaard

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
Blood|October 26, 2000
High levels of soluble syndecan-1 in myeloma-derived bone marrow: modulation of hepatocyte growth factor activityC Seidel, M Børset, O Hjertner, et al.
European Journal of Haematology|September 21, 2000
Biochemical markers of bone metabolism reflect osteoclastic and osteoblastic activity in multiple myelomaN Abildgaard, H Glerup, J Rungby, et al.
Blood|September 25, 2001
Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone diseaseC Seidel, Ø Hjertner, N Abildgaard, et al.
British Journal of Haematology|October 16, 1999
Prognostic evaluation in multiple myeloma: an analysis of the impact of new prognostic factorsI Turesson, N Abildgaard, T Ahlgren, et al.
Bone Marrow Transplantation|November 11, 2008
The polymorphism IL-1beta T-31C is associated with a longer overall survival in patients with multiple myeloma undergoing auto-SCTA J Vangsted, T W Klausen, W Ruminski, et al.
Bone Marrow Transplantation|June 30, 2015
Salvage bortezomib-dexamethasone and high-dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM with ASCT. A phase-2 trialP Gimsing, Ø Hjertner, N Abildgaard, et al.
Bone Marrow Transplantation|April 14, 2015
Autologous stem cell transplantation versus novel drugs or conventional chemotherapy for patients with relapsed multiple myeloma after previous ASCTM Grövdal, H Nahi, G Gahrton, et al.
Journal of Hematology & Oncology|January 18, 2018
Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert PanelJ Caers, B Paiva, E Zamagni, et al.
Leukemia|September 3, 2010
The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working GroupE Terpos, M A Dimopoulos, O Sezer, et al.
Blood Cancer Journal|August 26, 2017
Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: a study of the International Myeloma Working GroupJ Hillengass, L A Moulopoulos, S Delorme, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Blood|October 26, 2000
High levels of soluble syndecan-1 in myeloma-derived bone marrow: modulation of hepatocyte growth factor activityC Seidel, M Børset, O Hjertner, et al.
European Journal of Haematology|September 21, 2000
Biochemical markers of bone metabolism reflect osteoclastic and osteoblastic activity in multiple myelomaN Abildgaard, H Glerup, J Rungby, et al.
Blood|September 25, 2001
Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone diseaseC Seidel, Ø Hjertner, N Abildgaard, et al.
British Journal of Haematology|October 16, 1999
Prognostic evaluation in multiple myeloma: an analysis of the impact of new prognostic factorsI Turesson, N Abildgaard, T Ahlgren, et al.
Bone Marrow Transplantation|November 11, 2008
The polymorphism IL-1beta T-31C is associated with a longer overall survival in patients with multiple myeloma undergoing auto-SCTA J Vangsted, T W Klausen, W Ruminski, et al.
Bone Marrow Transplantation|June 30, 2015
Salvage bortezomib-dexamethasone and high-dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM with ASCT. A phase-2 trialP Gimsing, Ø Hjertner, N Abildgaard, et al.
Bone Marrow Transplantation|April 14, 2015
Autologous stem cell transplantation versus novel drugs or conventional chemotherapy for patients with relapsed multiple myeloma after previous ASCTM Grövdal, H Nahi, G Gahrton, et al.
Journal of Hematology & Oncology|January 18, 2018
Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert PanelJ Caers, B Paiva, E Zamagni, et al.
Leukemia|September 3, 2010
The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working GroupE Terpos, M A Dimopoulos, O Sezer, et al.
Blood Cancer Journal|August 26, 2017
Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: a study of the International Myeloma Working GroupJ Hillengass, L A Moulopoulos, S Delorme, et al.
Pageof 3